Structured penalized regression for drug sensitivity prediction
暂无分享,去创建一个
[1] Donald R. Jones,et al. Efficient Global Optimization of Expensive Black-Box Functions , 1998, J. Glob. Optim..
[2] Zijing Wang,et al. Efficient parameter selection for support vector machines , 2019, Enterp. Inf. Syst..
[3] Yu Jiang,et al. A Selective Review of Multi-Level Omics Data Integration Using Variable Selection , 2019, High-throughput.
[4] Roman Hornung,et al. Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data , 2018, BMC Bioinformatics.
[5] Frank Dondelinger,et al. The joint lasso: high-dimensional regression for group structured data , 2018, Biostatistics.
[6] Q. Ding,et al. Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation , 2018, Cancer medicine.
[7] Krister Wennerberg,et al. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach , 2017, Bioinform..
[8] Daniel C. Liebler,et al. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. , 2017, Gastroenterology.
[9] Reza Safdari,et al. Computational prediction of drug-drug interactions based on drugs functional similarities , 2017, J. Biomed. Informatics.
[10] Daniel V. Samarov,et al. A Coordinate-Descent-Based Approach to Solving the Sparse Group Elastic Net , 2017, Technometrics.
[11] A. Lusis,et al. Multi-omics approaches to disease , 2017, Genome Biology.
[12] Xiaoyu Jiang,et al. IPF-LASSO: Integrative L 1-Penalized Regression with Penalty Factors for Prediction Based on Multi-Omics Data , 2017, Comput. Math. Methods Medicine.
[13] A. Pandey,et al. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer , 2017, Oncotarget.
[14] C. I. Smith,et al. From identification of the BTK kinase to effective management of leukemia , 2016, Oncogene.
[15] D. Chan,et al. Precision medicine: from pharmacogenomics to pharmacoproteomics , 2016, Clinical Proteomics.
[16] R. Reis,et al. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. , 2016, Pharmacological research.
[17] Sungkyoung Choi,et al. Pathway-based approach using hierarchical components of collapsed rare variants , 2016, Bioinform..
[18] Scott E. Martin,et al. Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.
[19] I. Laurenzana,et al. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients , 2016, Oncotarget.
[20] Aida Moreno-Moral,et al. MT-HESS: an efficient Bayesian approach for simultaneous association detection in OMICS datasets, with application to eQTL mapping in multiple tissues , 2015, Bioinform..
[21] R. Plummer,et al. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Jin,et al. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis , 2015, Cell Death and Disease.
[23] Bin Nan,et al. Multivariate sparse group lasso for the multivariate multiple linear regression with an arbitrary group structure , 2015, Biometrics.
[24] H. Chen,et al. β2-AR signaling controls trastuzumab resistance-dependent pathway , 2015, Oncogene.
[25] Martin Sill,et al. c060: Extended Inference with Lasso and Elastic-Net Regularized Cox and Generalized Linear Models , 2014 .
[26] Wessel N van Wieringen,et al. Better prediction by use of co‐data: adaptive group‐regularized ridge regression , 2014, Statistics in medicine.
[27] Robert Clarke,et al. Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.
[28] Trevor Hastie,et al. A Blockwise Descent Algorithm for Group-penalized Multiresponse and Multinomial Regression , 2013, 1311.6529.
[29] Laura M. Heiser,et al. Modeling precision treatment of breast cancer , 2013, Genome Biology.
[30] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[31] O. Thas,et al. EMLasso: logistic lasso with missing data , 2013, Statistics in medicine.
[32] G. Silvestri,et al. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence. , 2013, Lung cancer.
[33] Noah Simon,et al. A Sparse-Group Lasso , 2013 .
[34] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[35] Hsiu-Fang Lee,et al. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. , 2012, Cancer research.
[36] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[37] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[38] F. Hodi,et al. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma , 2011, Clinical Cancer Research.
[39] I. Glad,et al. Weighted Lasso with Data Integration , 2011, Statistical applications in genetics and molecular biology.
[40] J. Blay,et al. Nilotinib: a novel, selective tyrosine kinase inhibitor. , 2011, Seminars in oncology.
[41] G. Rassidakis,et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21) , 2011, Leukemia.
[42] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[43] Xi Chen,et al. Smoothing proximal gradient method for general structured sparse regression , 2010, The Annals of Applied Statistics.
[44] Joel Greshock,et al. Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.
[45] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[46] E. Xing,et al. Tree-guided group lasso for multi-response regression with structured sparsity, with an application to eQTL mapping , 2009, 0909.1373.
[47] R. Hamatake,et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. , 2009, Cancer research.
[48] Jean-Philippe Vert,et al. Group lasso with overlap and graph lasso , 2009, ICML '09.
[49] J. M. Najeb,et al. Efficient Parameter Selection of Support Vector Machines , 2008 .
[50] Hongzhe Li,et al. Network-constrained regularization and variable selection for analysis of genomic data , 2008 .
[51] A. Zell,et al. Efficient parameter selection for support vector machines in classification and regression via model-based global optimization , 2005, Proceedings. 2005 IEEE International Joint Conference on Neural Networks, 2005..
[52] Stephen J. Wright,et al. Simultaneous Variable Selection , 2005, Technometrics.
[53] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[54] N. Ueno,et al. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[55] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[56] R. Gilbertson,et al. Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK* , 2003, Journal of Biological Chemistry.
[57] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[58] J. Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.
[59] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[60] D. Goodsell,et al. The Molecular Perspective: Methotrexate , 1999, Stem cells.
[61] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .